Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK plc reported a transaction involving Chief Scientific Officer Tony Wood related to its Deferred Investment Award Programme. On 18 February 2026, 25% of an award granted on 18 February 2021 vested. In connection with this vesting, Wood will receive a cash payment of £204,048.58, before tax, corresponding to 8,996.851 notional ordinary shares of 31¼ pence each, valued at £22.68 per share. This is recorded as a single transaction under GSK’s remuneration arrangements for senior management.
GSK plc reports that, acting through BNP Paribas, it repurchased 410,000 ordinary shares on 18 February 2026 as part of its existing share buyback programme. The shares, with a volume-weighted average price of 2,268.77p, will be held as treasury shares.
Since 17 February 2026, GSK has bought back a total of 830,000 ordinary shares. After these transactions, it holds 240,721,094 shares in treasury and has 4,075,421,475 ordinary shares in issue, which is also the total number of voting rights.
The company states that treasury shares now represent 5.91% of the voting rights. Detailed schedules list the prices and volumes of trades executed on the London Stock Exchange and Cboe Europe venues as part of this programme.
GSK plc repurchased 420,000 ordinary shares of 31¼ pence each on 17 February 2026, acting through BNP Paribas under a non-discretionary agreement as part of its existing share buyback programme. The shares were bought at prices between 2,189.00p and 2,259.00p, with a volume-weighted average price of 2,231.39p.
The repurchased shares will be held as treasury shares. After this transaction, GSK holds 240,311,094 ordinary shares in treasury and has 4,075,831,475 ordinary shares in issue excluding treasury shares, which is also the total number of voting rights. Treasury shares represent 5.90% of voting rights attributable to ordinary shares.
GSK plc reported a management share transaction involving President Maya Martinez-Davis. On February 13, 2026, performance share awards granted in 2020 under GSK’s 2017 Performance Share Plan vested, delivering 10,836.957 American Depositary Shares (ADS) at a price of $0.00 to the executive.
On the same date, 4,009.778 ADS were sold on the New York Stock Exchange at a price of $58.8509 per ADS to meet tax liabilities arising from the vesting. The remaining ADS from the award vesting continue to be held by the executive. These transactions reflect routine equity-based compensation and related tax settlement for a senior leader.
GSK plc reported that awards granted in 2023 under its 2017 Performance Share Plan for senior leaders vested at 82% of maximum, with 18% lapsing, after a three-year performance period to 31 December 2025. Vesting was driven by several business measures. Total sales over the period reached £99.03bn, above the £94.58bn level required for full vesting on that metric, while total profit was £30.22bn, above the £29.43bn 100% vesting hurdle. Total shareholder return ranked fifth in a peer group of 10 global pharmaceutical companies. Pipeline progress and responsible business environmental targets also achieved maximum vesting levels. On 13 February 2026, multiple PDMRs and one person closely associated received vested Ordinary Shares or ADS at no cost and sold portions at market prices, mainly around £21.6002 per Ordinary Share and $58.8509 per ADS, solely to meet tax liabilities.
GSK plc is launching the fourth tranche of its previously announced £2 billion share buyback programme. This new tranche allows buybacks of up to £0.45 billion of ordinary shares, with purchases expected between 17 February 2026 and 24 April 2026.
GSK has entered a non-discretionary agreement with BNP Paribas S.A., which will independently execute trades on specified European venues. Shares repurchased in this tranche will be held as treasury shares. The programme is intended to return excess capital, reduce share capital, and is expected to enhance earnings per share.
The fourth tranche will be conducted within GSK’s existing authority to repurchase up to 413,957,879 ordinary shares granted at its 2025 Annual General Meeting, and will comply with applicable UK and EU-derived market regulations. No repurchases will be made in the United States or in respect of American Depositary Receipts.
GSK reports that the European Commission has approved Exdensur (depemokimab) for two uses: add-on maintenance treatment for severe asthma with type 2 inflammation in patients 12 and older, and add-on therapy for adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP).
Exdensur is described as the first ultra-long-acting biologic in the EU for respiratory diseases, given just twice a year. In phase III SWIFT trials, adding depemokimab to standard care cut annualised severe asthma exacerbations by 58% and 48% in SWIFT-1 and SWIFT-2, and a pooled analysis showed a 72% reduction in clinically significant exacerbations needing hospital or emergency visits.
In ANCHOR phase III trials for CRSwNP, depemokimab improved nasal polyp scores and nasal obstruction ratings versus placebo, while overall side effect rates and severity were similar to placebo. Exdensur already has approvals in the US, UK and Japan, and depemokimab is being studied in additional type 2 inflammation conditions and COPD.
GSK plc has granted 2026 performance share plan awards to senior executives and set detailed performance measures for vesting. The conditional share awards run over a three-year period from 1 January 2026 to 31 December 2028 and are granted under the GlaxoSmithKline 2017 Performance Share Plan.
Each award’s vesting depends on five measures: total sales growth, core operating profit growth and pipeline sustainability at 17.5% each, a responsible business composite scorecard at 7.5%, and relative total shareholder return (TSR) at 40%. Dividends accrue during the period but only vest if the underlying awards vest.
For the CEO and other PDMRs, threshold vesting levels differ for some metrics, and awards that do not meet performance conditions will lapse. Executive Directors also face an additional two-year holding period after normal vesting, extending their total time horizon to five years.
GSK plc reported that senior leaders received deferred share bonuses for 2025 performance under its 2017 Deferred Annual Bonus Plan. On 12 February 2026, awards were granted mainly as Ordinary Shares priced at £21.50 and, for one executive, as ADS priced at $58.49.
The plan requires Executive Directors and Executive Committee members to defer a portion of their annual bonus into shares for three years. Examples include CEO Luke Miels receiving 27,962 Ordinary Shares and CFO Julie Brown receiving 55,178 Ordinary Shares, with additional awards to other committee members.
GSK plc reported that two senior executives received notional share awards under its Deferred Investment Award programme. On 12 February 2026, President Europe Lynn Baxter and Chief Patient Officer Mondher Mahjoubi were each granted awards over 3,020 notional Ordinary Shares at a reference price of £21.41 per share.
The awards are designed to reward outstanding performance during 2025 and align management with shareholders. They vest on 12 February 2029, provided the recipients remain with the company and are not terminated for cause. No dividends accrue during the vesting period and, on vesting, the awards will be settled in cash rather than actual shares. Executive Directors are not eligible to receive awards under this programme.